drugset / Trial / NCT01810432

Study of Food on Evacetrapib (LY2484595) in Healthy Participants

NCT01810432

Phase 1 Completed 40 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it when given to healthy participants. Information about any side effects that may occur will also be collected. The study has 2 periods. In each period, participants will take the study drug for 10 days, either with or without a meal. There is a minimum 14-day washout between each period. This study is approximately 50 days, not including screening. Screening is required within 28 days prior to the start of the study.

Timeline

Start
2013-03
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Evacetrapib Small molecule 130 mg Oral

Indications

No indication recorded.